Why The US FDA Requested Ranitidine Withdrawal; How Other Withdrawals Could Follow

 
• By Bowman Cox

Agency worried what might happen beyond expiry or room temperature to generate carcinogenic impurities in ranitidine; will guide assessment of nitrosamine risks in other drugs.

Molecule of ranitidine,
Ranitidine withdrawal driven by storage-related nitrosamine risks • Source: Shutterstock

More from Compliance

More from Pink Sheet